Ahmed Sarwar Murshed
Biography
Name: Dr. Ahmed Sarwar Murshed
Phone: 01713001320.
Email:drsrwar@yahoo.com
Education:
MBBS: Sylhet M A G Osmani Medical , Sylhet,1997
Fellowship in Interventional Oncology CAMCEN USA, Bangladesh unit in 2007
Training:
- 5 Year?s Training on PEI,TACE,RFA, MWA and Tumor ablation in St. Luke?s Cancer Center, PA USA and CAMCEN, Bangladesh from 2002- 2007 under supervision of Prof. Lee B. Riley, Director, St. Luke?s Cancer Center, Bethlehem, PA ,USA and Prof M A Hai, Professor of Clinical Oncology.
- 7 day?s Training on Liver Cancer Management in Gastroenterolgy Surgery Dept. M D Anderson Cancer Center, TX,USA in 2004 under Prof Steven Curley.
- 3 day?s advanced training on Laparoscopic RFA of HCC in UPMC Liver Cancer
Center, PA, USA in 2004 under Prof. David Galler.
- 7 days training on DEB TACE from Nanjing Liver Cancer Center, Nanjing China 2017
- 7 days training on HIAC from Hunan Institute of Liver Disease, Hunan China 2023
Experiences:
- Staff Physician, Surgical & Interventional Oncology in CAMCEN,USA Bangladesh Facility from 2007 to 2009
- Interventional Oncologist, American SuperSpecialty Hospital,32 Isha Khan Avenue Uttara Sector 6 ,Dhaka from 2009 (Jan to Jul)
- Consultant, Anwar Khan Mordern Hospital since 2009 .
- Visiting Consultant in Combined Military Hospital ,Dhaka since 2021
Clinical Research and experience:
Being the pioneer in the field of interventional oncology in Bangldaesh,I have performed open and CT guided RFA ,MWA and PEI in 4000 cases of primary and secondary liver cancers, primary and secondary Lung cancers , RCC, Primary and secondary bone cancers and other soft tissue sarcomas. While performing the procedures I have developed skills to ablate huge tumors and able to encounter the post therapeutic side effects and complications. Also Trained on TACE, I have teamed up with local hepatologists,radiologists and are perform TACE in LABAID.so far we have done 35 cases in last 5 years
Oral and Poster Presentations and awards:
- Author of ?Combination of RFA with Conventional Therapies have increased the disease free survival of NSCLC patients in Bangladesh? presented the paper in World Congress of Interventional Oncology and Best of ASCO in Los Angeles ,CA,USA in 2008
- Co Author of ? RFA along with chemotherapy and radiotherapy have improved the survival of advanced Lung Cancer Patients in Bangladesh ? presented by Prof Rashidul Hassan in WCIO in 2010 in New York,USA in 2010
- Author of Electronic Poster on ? Radiofrequency Ablation along with EBRT and/ or Chemotherapy have improved the complete treatment response rate of NSCLC ? which was accepted by CIRSE scientific committee during Copenhagen conference in 2008 (b
- Author of Paper on ?RFA along with PEI have improved the Survival HCC patients in Bangladesh? presented as poster In 7th SAARC Oncology Summit. The International jury rewarded me the first position. Prof M A Hai, Prof Syed Akram Hossain Dr. Mohsin Kabir were among the co Authors
- Author of the paper on ?RFA along with PEI has Improved Survival of Huge HCC patients in Bangladesh.? Presented in 25th Annual Conference of Association of Physicians of Bangladesh in 2014. The paper won the Best Free Paper in the conference.
- Paper on ?RFA yielded long term survival of small and medium size early stage RCC patients in Bangladesh. ? I presented the paper in 3 rd joint course of European School of Urology and Asian School of Urology held in Dhaka .
- Author of the Poster on Microwave ablation of NSCLC presented in PULMUCON 2017 in Bangladesh which has won the first position for extra ordinary research. Prof Rashidul Hassan,Prof Syed Akram Hoassain were the co Authors
- Author of the Poster on Microwave ablation of NSCLC along with conventional therapies have improved the survival of NSCLC patients in Bangladesh presented in PULMUCON 2019 in Bangladesh which has won the Ist Runner Up position for extra ordinary research. Prof Rashidul Hassan,Prof Syed Akram Hoassain,Prof Abdul Qayum were the co Authors
- Author of ? MWA along with chemotherapy and radiotherapy have improved the survival of advanced Lung Cancer Patients in Bangladesh ? presented by me in. CIRSE 2019,Barcelona,SPAIN.
- Author ofTreatment with Combination Transarterial Chemoembolization and Lenvatinib Plus Sequential Microwave Ablation Improves Survival in Patients with Unresectable Large Hepatocellular Carcinoma Beyond Up-to-7 Criteria presented in EASL Liver Cancer Summit in Paris France ,2025
Invited Faculty in International Societies:
- Faculty for delivering a talk on Ablation of Extra Large HCC in Indian Society for Vascular and Interventional Radiology 2017 held in Kolkata.
- Faculty for delivering speech on Interventional management of Extra Large Liver cancer in Asia Pacific Congress on Interventional Oncology 2017 in Delhi.
- Faculty in Asian Congress of Tumor Ablation , 2008 held in India. I delivered speech on Microwave Ablation of NSCLC
Professional Membership:
- Member Cardiovascular and Interventional Radiology Society of Europe
- Member Society of Interventional Oncology, USA
- Member European Association for the Study of the liver
- Treasurer, Bangladesh Society For Liver Cancer Treatment & Research
Research Interest
Abstract
The aim of this study was to investigate the efficacy and safety of transarterial chemoembolization (TACE) combined with Lenvatinib plus sequential microwave ablation (MWA) for the treatment of patients with large hepatocellular carcinoma (HCC) beyond up-to-seven criteria.
Methods: This multicenter prospective study included 135 patients diagnosed with Barcelona Clinic Liver Cancer Beyond Upto 7(BCLC B2) between January 2015 and January 2022. Participants were grouped into: i) Transarterial Chemoembolization with Lenvatinib plus sequential Microwave ablation group (TLM, n=47), and ii) Transarterial Chemoembolization and Microwave ablation group (TM, n=88). Each group was subdivided based on the largest tumor diameter: a) 7-8 cm, b) 8-10 cm, and c) >10 cm. In the TLM group, Lenvatinib was administered 7 days post-transarterial Chemoembolization(TACE), followed by Microwave Ablation( MWA) after 21 days. Lenvatinib was resumed after recovery from MWA . The TM group underwent MWA 7 days post-TACE. Progression-Free Survival (PFS), Overall Survival (OS), and complications were assessed.
Results: Technical success of combined transarterial chemoembolization and Microwave Ablation was achieved in all patients (100% either in single or multiple sessions). Follow-up MRI/CT was done to assess the treatment response after one month. The median follow up period was 48.5 months. The TLM group had longer PFS than the TM group (median, 17.32 vs. 6.3 months, p < 0.001; median.1,3,5 year cumulative over all survival of patients in TM group: 7-8 tumor subgroup: 96%, 72 %,42% ; in 8- 10 cm subgroup:87%, 45%,18%;in more than 10 cm tumor sub group: 48%,24%,3% and in TLM group: 7-8 tumor sub group: 95%,77%,51% ;in 8-10 tumor sub group: 92%,59%,32%;in more than 10 cm tumor sub group:61%, 34%,9%. There was no treatment related death. Minor complications like pain, fever, nausea occurred in 13% cases while major complications such as Hepatic failure, hemorrhage, pleural effusion occurred in 1% cases. The occurrence of major complications were seen mainly in Cirrhosis Child Pugh B patients irrespective of TLM or TM groups.
Conclusion: The combination of TACE, Lenvatinib, and sequential MWA improves PFS and OS in patients with large unresectable HCC beyond the up-to-seven criteria, with a high safety profile.
Keywords: Hepatocellular Carcinoma, Transarterial Chemoembolization, Lenvatinib, Microwave Ablation, Survival Analysis
